Xenon Genetics

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for patients with neurological and psychiatric disorders. The company leverages its deep expertise in ion channel biology and human genetics to target conditions such as epilepsy, depression, and pain. Its lead candidate, azetukalner (XEN1101), is a potent potassium channel opener that has demonstrated significant efficacy in Phase 3 trials for focal onset seizures and is being evaluated for major depressive disorder and bipolar depression. Xenon maintains a robust pipeline of both proprietary and partnered programs, including a significant collaboration with Neurocrine Biosciences. The company is headquartered in Burnaby, Canada, with additional operations in Boston, Massachusetts.